New chemo combo could boost stem cell transplant success for leukemia patients

NCT ID NCT07025824

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times

Summary

This study tests which of two chemotherapy drugs, treosulfan or melphalan, works better and causes fewer side effects when given before a stem cell transplant for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). About 220 adults who are already scheduled for a transplant will take part. The main goal is to see which drug helps people live longer, while also tracking relapse, graft-versus-host disease, and other complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I

    Dresden, Germany

    Contact

  • Universitätsklinikum Münster, Medizinische Klinik A, KMT-Zentrum

    Münster, Germany

    Contact

  • Universitätsklinikum Schleswig-Holstein, Campus Kiel

    Kiel, Germany

    Contact

  • Universitätsmedizin Halle (Saale)

    Halle, Germany

    Contact

Conditions

Explore the condition pages connected to this study.